Insiders Trades
IBA Stock: price and insider trades · Belgium
1 insider bought €226k of shares over the last 90 days, the latest filed 09 Sept 2026.
IBA: what insiders have been doing
Every trade that managers of IBA disclose to FSMA is tracked on this page. The company is based in Louvain-la-Neuve, Belgium. Between 18 October 2025 and 18 October 2026, 27 insiders published 53 filings.
Both sides are active: 41 purchases worth €2.1M and 9 sales worth €2.4M, from 26 insiders and 7 insiders respectively. The totals exclude 29 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a sale of €1.6M by Legrain Olivier, published on 15 July 2026, equal to 0.31% of the market capitalisation. Those buying include 19 senior executives and 5 board members.
In the case of 6 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 39 days ago, on 9 September 2026.
For context, the typical company on the same exchange (median of 77 companies) published 11 filings over the same period, against 53 filings here. Looking back to 2024, when coverage begins, insiders filed 49 purchases and 16 sales.
These figures are compiled from regulatory filings published by FSMA. They describe what insiders did and are not a recommendation.
Insider Decl.
68
Thresholds
n/a
Buy Volume
€3M
49 ops. · all time
Sell Volume
€3M
16 ops. · all time
Who traded when
BuySaleSwaenepoel Christophe6 buys4 sales
Van der Burght Marc5 buys4 sales
Legrain Olivier3 buys3 sales
Frédéric Genin3 buys2 sales
Forton Eric3 buys1 sale
Levratti Stephane4 buys
+19 other insiders
Since the insiders bought
- +4.6%Entry €15.24 · Close 13 Oct 2026 €15.94
- -6.2%Entry €17.00 · Close 13 Oct 2026 €15.94
- -6.2%Entry €17.00 · Close 13 Oct 2026 €15.94
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 15,708 of 24,148 companies
42.0
score / 100
Value33
Quality51
FCF yld-8.0%
Earn yld2.7%
EV/EBITDA16.3x
ROE21%
Gross mgn32%
Net mgn2.1%
Debt/EBITDA3.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€16.54
Analyst consensus
4 analysts2.00/5
€12.00Target €17.63(+7%)€20.50
Income statement
Revenue€620.2M
Gross profit€199.6M32% margin
EBITDA€36.5M6% margin
Net income€12.7M3.9% margin
Valuation
PER (trailing)20.2x
PER (forward)15.0x
P/Book4.1x
Beta1.26
Balance sheet & cash
Market cap€480.3M
Total debt€116.9M
Free Cash Flow-€38.4M
Debt / Equity100%
Profitability & ownership
ROE20.7%
ROA3.7%
% insiders36.6%
% institutions21.2%
Last declaration on 9 September 2026
Declarations68 total
3,967 shares@ €16.890.015% mcap17.1% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-103
5,000 shares@ €16.180.018% mcap20.7% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-100
11,983 shares@ €17.550.048% mcap30.2% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-40
3,967 shares@ €13.390.012% mcap13.6% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-37
Canonical exit: 12 Oct 2026 (T+90)
5,000 shares@ €13.390.015% mcap11.6% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-42
Canonical exit: 29 Nov 2026 (T+90)
9,861 shares0Options /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-92
Canonical exit: 2 Oct 2025 (T+90)
9,861 shares0Options /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-64
Canonical exit: 2 Oct 2025 (T+90)
9,861 shares0Options /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-59
Canonical exit: 2 Oct 2025 (T+90)
11,983 shares@ €13.390.032% mcap89.5% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-98
9,861 shares0Options /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-18
Canonical exit: 2 Oct 2025 (T+90)
95,870 shares@ €13.390.26% mcap38.1% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-94
Canonical exit: 20 Sept 2026 (T+90)
2,500 shares@ €7.540.0038% mcap33.4% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-99
Canonical exit: 21 Sept 2026 (T+90)
1,250 shares@ €7.54100.0% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-97
11,983 shares@ €13.390.036% mcap23.0% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-95
Canonical exit: 1 Oct 2026 (T+90)
95,870 shares@ €16.340.31% mcap46.5% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-93
3,945 shares@ €14.1045.6% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-54
2,500 shares@ €7.5410.5% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-91
Canonical exit: 27 Jun 2026 (T+90)
5,916 shares@ €11.2054.4% of flowOptions /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-90
5,916 shares0Options /warrants for employees or managersEuronext BrusselsISIN BE0003766806FSMA:iba-73
Canonical exit: 28 Sept 2025 (T+90)
2,500 shares@ €7.5433.4% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-81
Canonical exit: 26 Apr 2026 (T+90)
2,500 shares@ €7.4533.3% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-45
5,000 shares@ €15.4143.0% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-17
19,721 shares@ €11.4850.9% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-76
Canonical exit: 2 Oct 2025 (T+90)
10,000 shares@ €11.6729.8% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-80
5,000 shares@ €7.545.4% of flowShareEuronext BrusselsISIN BE0003766806FSMA:iba-79
Canonical exit: 25 Aug 2025 (T+90)
25 of 68 declarations
About IBA
IBA is a company listed on the XBRU market, specializing in the development of radiation therapy and nuclear medicine solutions.
